LATEST ONCOPRESCRIBE UPDATES
This is an example
Written by: Dr. Eric Lander Sponsored by Boehringer Ingelheim Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare and phenotypically aggressive malignancies arising from neuroendocrine cells. While EP-NECs …Extrapulmonary Neuroendocrine Carcinoma: Clinical Overview and Advances in DLL3 Targeted Therapy
Written by: Dr. Eric Lander Sponsored by Boehringer Ingelheim Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare and phenotypically aggressive malignancies arising from neuroendocrine cells. While EP-NECs …Apixaban vs Rivaroxaban in Acute VTE: Practice-Changing Insights for Oncology Clinicians
SUMMARY: The Center for Disease Control and Prevention (CDC) estimates that approximately 1-2 per 1000 individuals develop Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE) each year in the …Fixed-Duration vs Continuous Targeted Therapy in Frontline CLL: Insights from the Phase III CLL17 Trial
SUMMARY: The American Cancer Society estimates that for 2026, about 22,760 new cases of Chronic Lymphocytic Leukemia (CLL) will be diagnosed in the US and 4350 patients will die …Reassessing the Role of Carboplatin in Neoadjuvant Therapy for HER2-Positive Breast Cancer: Insights from the neoCARHP Trial
SUMMARY: Breast cancer is the most common cancer among women in the US and about 1 in 8 women (12%) will develop invasive breast cancer during …Late Breaking Abstract – ASCO GI: 2026. Identifying a Less Neurotoxic First-Line Backbone in Metastatic Esophagogastric Cancer: Insights from the LyRiCX Trial
SUMMARY: The American Cancer Society estimates that in the US, about 31,510 new cases of Gastric cancer will be diagnosed in 2026 and about 10,740 people will …Late Breaking Abstract – 2026 ASCO GU Symposium: Advancing Adjuvant Therapy in Clear Cell Renal Cell Carcinoma
SUMMARY: The American Cancer Society estimates that 80,450 new cases of kidney and renal pelvis cancers will be diagnosed in the United States in 2026 and about 15,160 …Expanding Targeted First-Line Options in BRAF V600E–Mutant Metastatic Colorectal Cancer: Insights From the BREAKWATER Trial
SUMMARY: Colorectal cancer (CRC) is the third most common cancer diagnosed in both men and women in the United States. The American Cancer Society estimates that approximately 158,850 new cases …
NEW REGIMENS ADDED
VYLOY® with mFOLFOX 6 - for Gastric and GEJ cancer
VYLOY® (Zolbetuximab) with ELOXATIN® (Oxaliplatin), 5-FU and Leucovorin. Regimen for Gastric and GastroEsophageal Junction adenocarcinoma whose tumors are Claudin (CLDN) 18.2 positiveVYLOY® with CAPOX - for Gastric and GEJ cancer
VYLOY® (Zolbetuximab) with ELOXATIN® (Oxaliplatin) and XELODA® (Capecitabine). Regimen for Gastric and GastroEsophageal Junction adenocarcinoma whose tumors are Claudin (CLDN) 18.2 positiveENHERTU® - for Breast Cancer
Single Agent ENHERTU® (fam-trastuzumab deruxtecan-nxki) for Ultralow Metastatic Breast CancerOPDIVO® and YERVOY® with Limited Course Chemotherapy - for Non Small Cell Lung Cancer
OPDIVO® (Nivolumab) and YERVOY® (Ipilimumab) with 2 cycles of TAXOL® (Paclitaxel) and PARAPLATIN®(Carboplatin) - for advanced NSCLCJAYPIRCA® - for Mantle Cell Lymphoma
JAYPIRCA® (Pirtobrutinib) for Mantle Cell Lymphoma
Curbside Consultation
Bottom Ad
Advertisement
Subscribe
